Siltuximab is a chimeric human-mouse monoclonal antibody to interleukin-6 which is used in the therapy of Castleman disease. Siltuximab commonly causes mild serum aminotransferase elevations which are usually short lived and asymptomatic, but it has not been linked to instances of clinically apparent liver injury with jaundice.